m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG00555)
Name
KRN-2391
Synonyms
Ki-3315
    Click to Show/Hide
Status
Discontinued in Phase 2
Structure
3D MOL
2D MOL
Formula
C10H13N5O6S
InChI
1S/C9H9N5O3.CH4O3S/c10-7-13-9(8-2-1-3-11-6-8)12-4-5-17-14(15)16;1-5(2,3)4/h1-3,6H,4-5H2,(H,12,13);1H3,(H,2,3,4)
InChIKey
BIBJJSCMCXFMML-UHFFFAOYSA-N
PubChem CID
123957
TTD Drug ID
D0S6SU
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Sulfonylurea receptor 2 (ABCC9)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Sulfonylurea receptor 2 (ABCC9) is a therapeutic target for KRN-2391. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of KRN-2391 through regulating the expression of Sulfonylurea receptor 2 (ABCC9). [1], [2]
References
Ref 1 TRIM11 facilitates chemoresistance in nasopharyngeal carcinoma by activating the Beta-catenin/ABCC9 axis via p62-selective autophagic degradation of Daple. Oncogenesis. 2020 May 7;9(5):45. doi: 10.1038/s41389-020-0229-9.
Ref 2 Mechanism of disopyramide-induced hypoglycaemia in a patient with Type 2 diabetes. Diabet Med. 2009 Jan;26(1):76-8. doi: 10.1111/j.1464-5491.2008.02619.x.